Clinical Trial

The Impact of Intra-operative Fluid Infusion Rate on Microcirculation

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 27, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Intraoperative fluid therapy (IFT) is an integral part of anesthesia care during surgery. Its main indication is the optimization of oxygen supply to the tissues. For elective surgery that is not associated with higher blood loss and a long period of preoperative fasting, including fluids IFT is dosed to cover the basal daily need for fluids. However, it is not clear whether this fluid dose is optimal. Surgery is a stress factor that leads, among other things, to damage of the endothelial glycocalyx (EG). EG binds a significant amount of plasma, which is released during EG destruction and causes relative hemodilution. Isovolumic hemodilution is an established intraoperative procedure that serves to better control bleeding in procedures where bleeding is expected. However, partial hemodilution occurs even with standard IFT, and even when fluids are hardly given at all. Flow parameters in microcirculation have not yet been described depending on IFT conduction. The parameters of the microcirculation reflect its functioning, which will consequently affect the postoperative phase of the patient's moaning and clinical outcome.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-10-31; most recent amendment 2025-03-24.
Trial Details
NCT Number NCT05606536
Lead Sponsor University Hospital Hradec Kralove
Conditions Fluid Therapy, Microcirculation, Hemodilution
Enrollment 80 participants
Start Date 2022-10-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-03-27